Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC
B.RichterS.HenrichS.CzodrowskiP.RippmannF.WadeR
In Phase 2 studies, participants lost up to 1619% of body weight over 46 weeks, comparable to or greater than leading GLP-1 drugs
A. V. Arutjunyan, I. G. Popovich, L. S. Kozina, and G. A. Ryzhak, Peptide Regulation of Ageing: From Experiment to Practice, Bentham Science Publishers Ltd., Feb. 2025. doi: 10.2174/0118746098346230250116065407
